ArticleACS omega2026
ROS-Mediated Apoptosis Induction by a Cationic Pyridoxal Benzoylhydrazone Copper Complex in Oral Cancer Cells.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dual facets of copper in the malignant transformation of oral submucous fibrosis: A narrative review.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of novel therapeutic agents for oral squamous cell carcinoma (OSCC) remains an urgent clinical challenge. This study presents the synthesis and comprehensive biological evaluation of a new Cu complex derived from pyridoxal benzoylhydrazone. Single-crystal X-ray diffraction confirmed its distinct molecular structure. The complex demonstrated superior and selective cytotoxicity against a panel of cancer cell lines, particularly exhibiting potent activity against HSC-2 oral cancer cells, which was approximately 7.2-fold more potent than the clinical drug cisplatin. Notably, it showed a favorable selectivity index between that of HSC-2 and normal oral epithelial (HOK) cells. Mechanistic investigations revealed that the Cu complex exerts its potent anticancer effect through a pro-oxidant mechanism. It effectively disrupted redox homeostasis by depleting glutathione (GSH), elevating reactive oxygen species (ROS), and triggering a collapse of the mitochondrial membrane potential (ΔΨ
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.